Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. - Wikidata - wikimedia - TriplyDB

Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.

Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.

http://www.wikidata.org/entity/Q36995447

about

Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease Lysosomal storage diseases and the heat shock response: convergences and therapeutic opportunities Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina.Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease Common and uncommon pathogenic cascades in lysosomal storage diseases Genetic screening of Fabry patients with EcoTILLING and HRM technology.Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings.Cerebral hemodynamics and endothelial function in patients with Fabry disease Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice.Innate and Adaptive Immune Response in Fabry Disease Evaluation of oxidative stress markers and cardiovascular risk factors in Fabry Disease patients Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease.Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells.Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease Involvement of ROS in BBB dysfunction.Liver-specific deletion of the Plpp3 gene alters plasma lipid composition and worsens atherosclerosis in apoE-/- mice.Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature?Fabry's disease: an example of cardiorenal syndrome type 5.Altered Met Receptor Phosphorylation and LRP1 Mediated Uptake in Cells Lacking Carbohydrate-Dependent Lysosomal Targeting.Globotriaosylsphingosine induces oxidative DNA damage in cultured kidney cells.Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.HIV Tat Domain Improves Cross-correction of Human Galactocerebrosidase in a Gene- and Flanking Sequence-dependent Manner.Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease.Integrative Systems Biology Investigation of Fabry Disease.Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.Pathomechanisms of renal Fabry disease.Fabry disease and Factor V Leiden: a potent vascular risk combination.

P2860

Q21202889-0EAAF6C4-15AE-4992-ADD6-B1D09193BAD3 Q24650910-22BB17BC-CF28-4A22-A4B2-7903EDDACB2D Q27004531-B27EDD4F-48D0-46F4-8013-C60B285E7650 Q28727768-EBAA1A93-3771-4B15-B5BC-1EDD4CCDD06E Q28730130-8FECA5E2-CCD9-4812-80F0-DC2D237C228C Q30494447-6E1919E1-3915-4831-8607-6778E54BA824 Q33645550-C7576D7D-16A1-4D2E-AFF8-CBA6B68BBC8B Q33726258-57A36923-A36B-4D17-9F36-9E24D5223F51 Q33831482-FA15B5F6-5AC8-43AF-91BC-C57E2A763EC3 Q33937755-06110A5F-66E0-4024-9940-DBAC4E4E6D72 Q33966917-725D091D-6489-4C90-B3BD-52508FB287DD Q34012395-C8482D34-D8EF-45E9-AD57-0997F21EE02A Q34257466-DA0EC445-C114-4261-89EA-4978E158B58C Q34577897-0693CC57-BAD9-4085-AB6E-8B8E99619CE5 Q35037435-C2D3AA5F-7A66-4F45-B2DF-FDFC81834167 Q35152240-D8A1343A-5F04-442A-A035-C80FA6FD3C67 Q35800976-D8553BF7-6786-490D-9B0E-7622DC9FEBE3 Q36075584-42EB6988-CFFE-46CD-ACE2-4D6D5964F60C Q36189989-72F14EBF-58E5-4F52-85A3-45594083BFFA Q36219290-B06359FF-A0C5-4295-AC50-DF414CFF1760 Q36475780-AE9489C0-2E6E-4EB5-8004-1E931C86D3FD Q36565901-A13425F0-1421-4CA6-92A8-4609E379A381 Q37329223-7D854C3E-F677-4217-B1B9-007850977A3C Q37400756-70701428-19F0-464A-A969-B3920E368783 Q37698833-E8ABC0F9-34A4-4851-9BDB-A82C9DF3E9BF Q38152826-0165B9F5-F828-46D2-AD6F-052C1B645663 Q38558725-777480E8-F7C5-4694-B69F-D67B8884C539 Q38671502-679967F1-38C1-41F8-8DFA-6A0B82704CB0 Q38827299-924C811B-A3A1-494C-8498-D2E770C9D77A Q38844401-789C78A0-AB00-4BAF-8ED1-521B8EBDB26F Q39636269-16A94196-4883-42C1-A9FC-4696D4A26104 Q39776866-EA67F3E9-559C-4D43-B46B-80DE4692ECA0 Q40351353-5C53A21C-C959-4D9F-B1BC-5DCE45B216FC Q41689988-C687A039-6757-4AC0-94F7-9E41C3DA1C99 Q42110868-DA4EA2F2-056D-4794-9982-BFFB58A58B01 Q42599584-A2185FCE-2271-4339-ABBB-38BD24D17E85 Q47094778-0D84083B-6763-45F2-9965-B14471C0424A Q47123134-8256F968-CD93-4257-9AB2-6769AD52F1EB Q48287690-581E3DD9-B408-44B1-86E2-4F4BAC1D506E Q48664517-F0DF35E3-570A-4654-A130-B17AD85E967B

P2860

Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.

http://www.wikidata.org/entity/Q36995447

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Globotriaosylceramide induces ...... bry disease endothelial cells.

@en

type

label

Globotriaosylceramide induces ...... bry disease endothelial cells.

@en

prefLabel

Globotriaosylceramide induces ...... bry disease endothelial cells.

@en

P1433

Q36995447-0B2FEF73-68D2-48F2-B2FF-86DFCF4FA61C

P1476

Q36995447-9844D13B-6EF0-4AF1-8D05-38CE050DB479

P2093

Q36995447-0CB8A412-A801-48F6-BFDF-25CE1C360DDF

Q36995447-2269078F-711A-43D3-88BA-E64D99BC242E

Q36995447-477EF88B-A5D3-4F4F-9DCD-97DD419268A4

Q36995447-A415BFB1-668B-4AD9-B5B0-4F97F2BD7EAA

Q36995447-E8C58F5B-F4FD-4DD1-A8BF-E6C02AE9A55D

Q36995447-F0CB479D-C99E-4B9C-A041-2BDA653AD026

P2860

Q36995447-006BA2D8-EDDA-4932-9695-9FF4E186A55E

Q36995447-0F1B8C2E-C031-4020-B5F9-C42F822D3B62

Q36995447-13E8E1A3-74AA-451E-B9CE-2CB2B86B6F62

Q36995447-14016B20-44FF-463E-BA82-E7F5774A16A1

Q36995447-15F7F2BD-0894-4D08-91B9-AB48CCD98ED0

Q36995447-1AFF20D8-A18F-48EB-8F7E-98BA4C1DA346

Q36995447-24D259B3-5B34-421A-89BD-C06990ECABAF

Q36995447-2E99AC2A-CD16-4ECC-98EA-722FBE775393

Q36995447-2F8A894B-BCBE-44B6-BFEF-AE8864EA9698

Q36995447-4126ACAF-F512-4D4A-BAE9-E7109A6838B2

P304

Q36995447-EFF0797C-64D9-45D1-96F5-1BAEE262F970

P31

Q36995447-57A9D0BD-D943-4076-B0E9-4494FE31D233

P356

Q36995447-9EDC9093-B07C-4F5B-B945-ED85F8CA0EEA

P433

Q36995447-FE627345-5D88-4D81-BBCE-76824D0525D0

P478

Q36995447-CF4097F2-AB40-4D33-9F9F-C9679AC23FCB

P50

Q36995447-FA968329-5600-492B-80FB-68C2CAF0DF77

P577

Q36995447-F969846C-7AEA-4971-B499-AB52315E49DA

P5875

Q36995447-909DFDDE-F4B9-43AD-BB78-23C176717D4D

P698

Q36995447-EF0D1856-F29A-4131-9DEE-C57D297CEDA0

P921

Q36995447-A6D6D6B8-D912-4A1E-AC92-15C21C650BC4

P932

Q36995447-1FDDC377-0B82-47FA-B86A-28197C64F226

P356

J.YMGME.2008.06.016

P1433

Molecular Genetics and Metabolism

P1476

Globotriaosylceramide induces ...... abry disease endothelial cells

@en

P2093

David F Moore

http://www.w3.org/2001/XMLSchema#string

James A Shayman

http://www.w3.org/2001/XMLSchema#string

Jane M Quirk

http://www.w3.org/2001/XMLSchema#string

Jin-Song Shen

http://www.w3.org/2001/XMLSchema#string

Raphael Schiffmann

http://www.w3.org/2001/XMLSchema#string

Xing-Li Meng

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro

Uptake and metabolism of a fluorescent sulfatide analogue in cultured skin fibroblasts

Enhanced endothelium-dependent vasodilation in Fabry disease

Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency

Role of oxidative modifications in atherosclerosis

Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

Multiple role of reactive oxygen species in the arterial wall.

Adhesion molecules and atherosclerosis.

Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease.

P304

163-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YMGME.2008.06.016

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Christine R. Kaneski

P577

2008-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23175376

http://www.w3.org/2001/XMLSchema#string

P698

18707907

http://www.w3.org/2001/XMLSchema#string

P921

P932

2593623

http://www.w3.org/2001/XMLSchema#string